Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors

  • Authors:
    • Yuko Hayashi
    • Hidefumi Sasaki
    • Sho Takeshita
    • Ryutaro Nishikawa
    • Hiroshi Nishikawa
    • Atsushi Arakawa
    • Yoriko Yamashita
    • Satoru Takahashi
    • Mayumi Sugiura-Ogasawara
  • View Affiliations

  • Published online on: August 25, 2014     https://doi.org/10.3892/or.2014.3442
  • Pages: 1815-1819
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Serous borderline tumors and low-grade serous adenocarcinomas typically exhibit a low mitotic index and are largely resistant to chemotherapy. They are characterized by specific mutations, including mutations of KRAS and BRAF, which target specific cell signaling pathways. Mutational analyses may provide further insight into the development sequence of low-grade serous carcinomas. There are 3 methods to detect BRAF mutations: direct sequencing, such as Sanger sequencing (Sas); immunohistochemistry (IHC); and competitive allele-specific hydrolysis probe (TaqMan) PCR technology (CAST-PCR). In the present study, we matched the results of these 3 methods in ovarian serous borderline tumor cases. This study was carried out in 11 surgically removed ovarian serous borderline tumors. Detection of the BRAF V600E mutation was carried out by the FLEX detection system using the VE1 clone antibody and the results were compared with those of Sas and CAST-PCR. The autostainer IHC VE1 assay was positive in 3 of the 11 ovarian serous borderline tumors and negative in the remaining 8 tumors. CAST-PCR demonstrated a BRAF V600E mutation ratio of 16.4, 17.7 and 12.7%, respectively, in the 3 IHC-positive cases. Sas detected the BRAF V600E mutation in only 2 cases, while revealing wild-type BRAF in the remaining 9 cases. Sas revealed KRAS mutations in 2 of these 9 cases with wild-type BRAF. Our data suggest a high concordance rate of the results between CAST-PCR and IHC. Thus, IHC using the VE1 clone and FLEX linker is a specific method for the detection of BRAF V600E and may be an alternative to molecular-biologic techniques for the detection of mutations in ovarian serous borderline tumors. This method may be a useful screening method for the BRAF mutation.
View Figures
View References

Related Articles

Journal Cover

November-2014
Volume 32 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hayashi Y, Sasaki H, Takeshita S, Nishikawa R, Nishikawa H, Arakawa A, Yamashita Y, Takahashi S and Sugiura-Ogasawara M: Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors. Oncol Rep 32: 1815-1819, 2014
APA
Hayashi, Y., Sasaki, H., Takeshita, S., Nishikawa, R., Nishikawa, H., Arakawa, A. ... Sugiura-Ogasawara, M. (2014). Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors. Oncology Reports, 32, 1815-1819. https://doi.org/10.3892/or.2014.3442
MLA
Hayashi, Y., Sasaki, H., Takeshita, S., Nishikawa, R., Nishikawa, H., Arakawa, A., Yamashita, Y., Takahashi, S., Sugiura-Ogasawara, M."Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors". Oncology Reports 32.5 (2014): 1815-1819.
Chicago
Hayashi, Y., Sasaki, H., Takeshita, S., Nishikawa, R., Nishikawa, H., Arakawa, A., Yamashita, Y., Takahashi, S., Sugiura-Ogasawara, M."Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors". Oncology Reports 32, no. 5 (2014): 1815-1819. https://doi.org/10.3892/or.2014.3442